Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie nipokalimabu u těhotenství s rizikem těžkého hemolytického onemocnění plodu a novorozence (HDFN) (AZALEA)

2. listopadu 2026 aktualizováno: Janssen Research & Development, LLC

Randomizovaná, placebem kontrolovaná, dvojitě zaslepená, multicentrická studie fáze 3 k hodnocení účinnosti a bezpečnosti nipokalimabu u těhotenství s rizikem těžkého hemolytického onemocnění plodu a novorozence (HDFN)

The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn.

Přehled studie

Postavení

Nábor

Typ studie

Intervenční

Zápis (Odhadovaný)

120

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

      • Buenos Aires, Argentina, C1199
        • Nábor
        • Hospital Italiano de Buenos Aires
      • Córdoba, Argentina, X5016KEH
        • Nábor
        • Hospital Privado Universitario De Cordoba
      • South Brisbane, Austrálie, 4101
        • Nábor
        • Mater Hospital Brisbane
      • Sydney, Austrálie, 2170
        • Nábor
        • Liverpool Hospital
      • Brussels, Belgie, 1020
        • Nábor
        • C.H.U. Brugmann
      • Leuven, Belgie, 3000
        • Nábor
        • Universitair Ziekenhuis Leuven
      • Belo Horizonte, Brazílie, 30130 100
        • Nábor
        • Faculdade de Medicina Universidade Federal de Minas Gerais
      • Goiânia, Brazílie, 74605 020
        • Nábor
        • Hospital das Clinicas - UFG
      • Recife, Brazílie, 50070902
        • Nábor
        • Instituto de Medicina Integral Professor Fernando Figueira
      • Rio de Janeiro, Brazílie, 22281 100
        • Nábor
        • IDOR - Regional Rio de Janeiro
      • São Paulo, Brazílie, 05403-010
        • Nábor
        • Hospital Das Clinicas Da Faculdade De Medicina Da USP
      • Bron, Francie, 69500
        • Nábor
        • Hospices Civils de Lyon - Groupement Hospitalier Est - Hopital Femme Mere Enfant
      • Lille, Francie, 59000
        • Nábor
        • CHRU Lille
      • Paris, Francie, 75012
        • Nábor
        • Hopital Armand Trousseau
      • Leiden, Holandsko, 2333 ZA
        • Nábor
        • Leiden University Medical Center
      • Dublin, Irsko, D01 P5W9
        • Nábor
        • Rotunda Hospital
      • Roma, Itálie, 00168
        • Nábor
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Jerusalem, Izrael, 91240
        • Nábor
        • Hadassah mount scopus
      • Petah Tikva, Izrael, 49100
        • Nábor
        • Rabin Medical Center
      • Ramat Gan, Izrael, 5265601
        • Nábor
        • The Chaim Sheba Medical Center
      • Fukuoka, Japonsko, 812 8582
        • Dokončeno
        • Kyushu University Hospital
      • Gifu, Japonsko, 500-8717
        • Nábor
        • Gifu Prefectural General Medical Center
      • Izumi-shi, Japonsko, 594-1101
        • Nábor
        • Osaka Womens and Childrens Hospital
      • Sendai, Japonsko, 989-3126
        • Dokončeno
        • Miyagi Childrens Hospital
      • Ōta-ku, Japonsko, 143-8541
        • Nábor
        • Toho University Medical Center Omori Hospital
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3N1
        • Nábor
        • BC Women's Hospital University of British Columbia
    • Ontario
      • Toronto, Ontario, Kanada, M5G 1X5
        • Nábor
        • Mount Sinai Hospital
    • Quebec
      • Montreal, Quebec, Kanada, H4A 3J1
        • Nábor
        • McGill University Health Centre
      • Montreal, Quebec, Kanada, H3T 1C5
        • Nábor
        • Centre Hospitalier Sainte Justine
      • Berlin, Německo, 10117
        • Nábor
        • Charite Universitaetsmedizin Berlin
      • Giessen, Německo, 35392
        • Nábor
        • Universitaetsklinikum Giessen und Marburg Standort Giessen
      • Hamburg, Německo, 20251
        • Nábor
        • Universitaetsklinikum Hamburg Eppendorf
      • Lodz, Polsko, 93 338
        • Nábor
        • Instytut Centrum Zdrowia Matki Polki
      • Warsaw, Polsko, 01 211
        • Nábor
        • Instytut Matki i Dziecka
      • Warsaw, Polsko, 02 507
        • Nábor
        • Panstwowy Instytut Medyczny MSWiA w Warszawie
      • Graz, Rakousko, 8036
        • Nábor
        • Medizinische Universitaet Graz
      • Vienna, Rakousko, 1090
        • Nábor
        • Medizinische Universitaet Wien
      • Birmingham, Spojené království, B15 2TG
        • Nábor
        • Birmingham Women's Hospital
      • Leeds, Spojené království, LS9 7TF
        • Nábor
        • Leeds Teaching Hospitals NHS Trust
      • London, Spojené království, SE5 9RS
        • Nábor
        • Kings College Hospital
      • London, Spojené království, SW17 0QT
        • Nábor
        • St Georges Hospital
      • Manchester, Spojené království, M13 9WL
        • Nábor
        • St.Mary's Hospital
      • Oxford, Spojené království, OX3 9DU
        • Nábor
        • John Radcliffe Hospital
    • California
      • La Jolla, California, Spojené státy, 92037
        • Nábor
        • University of California at San Diego
      • Los Angeles, California, Spojené státy, 90027
        • Nábor
        • Kaiser Permanente Los Angeles Medical Center
      • Sacramento, California, Spojené státy, 95817
        • Nábor
        • UC Davis School of Medicine
    • Colorado
      • Aurora, Colorado, Spojené státy, 80045
        • Nábor
        • Childrens Hospital Colorado
    • Florida
      • Miami, Florida, Spojené státy, 33136
        • Nábor
        • University of Miami
    • Illinois
      • Park Ridge, Illinois, Spojené státy, 60068
        • Nábor
        • Advocate Children's Hospital
    • Indiana
      • Indianapolis, Indiana, Spojené státy, 46202
        • Pozastaveno
        • Riley Children s Hospital
    • Iowa
      • Iowa City, Iowa, Spojené státy, 52242
        • Nábor
        • University of Iowa
    • Kentucky
      • Lexington, Kentucky, Spojené státy, 40536
        • Nábor
        • University of Kentucky Medical Center
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21287
        • Nábor
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02115
        • Nábor
        • Boston Childrens Hospital
    • Minnesota
      • Minneapolis, Minnesota, Spojené státy, 55404
        • Nábor
        • Midwest Fetal Care Center
    • New York
      • New York, New York, Spojené státy, 10032
        • Nábor
        • Columbia University Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Spojené státy, 27599-7516
        • Nábor
        • University of North Carolina (UNC) - School of Medicine
    • Ohio
      • Cincinnati, Ohio, Spojené státy, 45267
        • Nábor
        • University of Cincinnati
    • Oregon
      • Portland, Oregon, Spojené státy, 97239
        • Nábor
        • Oregon Health and Science University
    • Pennsylvania
      • Allentown, Pennsylvania, Spojené státy, 18103-6218
        • Nábor
        • Lehigh Valley Hospital
    • Texas
      • Austin, Texas, Spojené státy, 78723
        • Nábor
        • University of Texas Dell Medical School Department of Women's Health
      • Galveston, Texas, Spojené státy, 77555
        • Nábor
        • University Of Texas Medical Branch At Galveston
    • Utah
      • Murray, Utah, Spojené státy, 84107
        • Nábor
        • Intermountain Medical Center
    • Virginia
      • Norfolk, Virginia, Spojené státy, 23507
        • Nábor
        • Macon & Joan Brock Virginia Health Sciences at Old Dominion University
    • Washington
      • Seattle, Washington, Spojené státy, 98105
        • Nábor
        • Seattle Children's Hospital
      • Barcelona, Španělsko, 08035
        • Nábor
        • Hosp Univ Vall D Hebron
      • Madrid, Španělsko, 28046
        • Nábor
        • Hosp. Univ. La Paz
      • Seville, Španělsko, 41013
        • Nábor
        • Hosp. Virgen Del Rocio
      • Stockholm, Švédsko, 14186
        • Nábor
        • Karolinska Universitetssjukhuset Huddinge

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 45 let (Dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Ženský

Popis

Inclusion Criteria:

  • Pregnant and an estimated gestational age (GA) (based on ultrasound dating) from Week 13^0/7 to Week 18^6/7 at randomization

  • History of severe Hemolytic Disease of the Fetus and Newborn (HDFN) in a prior pregnancy defined as documented:

    1. fetal anemia as result of HDFN or fetal hydrops as result of HDFN or received greater than or equal to (>=)1 IUT as a result of HDFN or
    2. fetal loss or neonatal death as a result of HDFN, with maternal alloantibody titers for Rhesus antigen D protein (RhD), Kell, Kell Rhesus antigen C protein (Rhc), Rhesus antigen E protein (RhE), or RhC antigen above the critical levels (anti-Kell >=4; other >=16) and evidence of an antigen-positive fetus
  • During the current pregnancy, presence of maternal alloantibody to RhD, Rhc, RhE, or RhC antigen with titers above the critical level (anti-Kell >= 4; other >=16) based on the designated central lab results at screening

  • Evidence of antigen-positivity corresponding to the current maternal alloantibody (RhD, Kell, Rhc, RhE, or RhC) confirmed by non-invasive antigen cell-free fetal DNA (cffDNA) performed at the central laboratory

  • Have screening lab test results within values within the study protocol-specified parameters: a) albumin >= lower limit of normal (LLN); b) alanine transaminase (AST) less than or equal to (<=) 2 × upper limit of normal (ULN); c) alanine transaminase (ALT) <=2 × ULN d) creatinine <=0.8 milligrams per deciliter (mg/dL), SI: <=70.7 micromole per liter (μmol/L), and Serum total immunoglobulins G (IgG) ≥ 600 mg/dL SI: >=6 g/L

  • Medically stable on the basis of physical examination, medical history, vital signs, 12-lead ECG, and clinical lab tests performed at screening

Exclusion Criteria:

  • Currently pregnant with a multiple gestation (twins or more)
  • Evidence of fetal anemia prior to randomization in the current pregnancy
  • History of severe preeclampsia prior to GA Week 34 or severe fetal growth restriction (estimated fetal weight <3rd percentile, based on local fetal growth normative standards) in a previous pregnancy
  • Current uncontrolled hypertension
  • History of myocardial infarction, unstable ischemic heart disease, or stroke
  • Has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Has inflammatory or autoimmune diseases requiring immunosuppressive therapies that may jeopardize the safety of the participant
  • Currently has a malignancy or has a history of malignancy within 3 years before screening (with the exception of localized basal cell carcinoma and/or squamous cell carcinoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study intervention administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study intervention)
  • Is currently receiving systemic corticosteroids or other immunosuppressants for disorders unrelated to the pregnancy
  • Has received or planning to receive plasmapheresis, immunoadsorption therapy, intravenous immunoglobulin (IV Ig), or any immunoglobulin (Ig)G fragment crystallizable (Fc)-related protein therapeutics during the current pregnancy
  • Has a severe infection including opportunistic infections
  • Presence of abnormal (protocol-specified) hematologic lab values during screening
  • History of an unprovoked pulmonary embolism or history of recurrent deep vein thrombosis (DVT)

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Nipocalimab

Participants will receive nipocalimab intravenously (IV) once weekly (qw) from randomization through gestational age (GA) Week 35.

Nipocalimab will be administered as an intravenous infusion.

Ostatní jména:
  • JNJ-80202135
  • M281
  • JNJ-86507083
Komparátor placeba: Placebo

Participants will receive matching placebo IV qw from randomization through GA Week 35.

Placebo will be administered as an intravenous infusion.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percentage of Pregnancies That did not Result in Fetal Loss, Intrauterine Transfusion (IUT), Hydrops Fetalis, or Neonatal Death
Časové okno: From randomization in the study through 4 weeks of age or 41 weeks Postmenstrual Age (PMA) during neonatal period, whichever is later

Percentage of pregnancies that did not result in fetal loss, IUT, hydrops fetalis, or neonatal death (during the neonatal period) will be reported. Hydrops fetalis is defined as the presence of greater than or equal to(>=)2 abnormal fluid collections in the fetus or neonate, such as ascites, pleural effusions, pericardial effusion, and generalized skin edema (skin thickness greater (>)5 millimeter [mm]). PMA is the time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (chronological age).

From randomization in the study through 4 weeks of age or 41 weeks Postmenstrual Age (PMA) during neonatal period, whichever is later

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of Participants With Hemolytic Disease of the Fetus and Newborn (HDFN) by Severity
Časové okno: For first database lock: from randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later for the first database lock; for second database lock: through 12 weeks after birth

Number of participants with HDFN by severity will be reported. The severity of HDFN is defined as: 5 (fatal): fetal or neonatal death due to any reason; 4 (severe): hydrops fetalis (in fetus or newborn) or receiving IUT during pregnancy as a result of HDFN but not 5 (fatal); 3 (moderate): neonatal exchange transfusions received as a result of HDFN related hemolysis and jaundice but not 4 (severe) or 5 (fatal); 2 (mild): neonatal simple transfusions received due to HDFN after birth, with or without phototherapy, but not 3 (moderate), 4 (severe), or 5 (fatal); and 1 (minimal or none): not in 2 (mild), 3 (moderate), 4 (severe), or 5 (fatal) as described above. Here database lock implies the last participant has given birth or terminated their pregnancy, completed the Week 4 visit after delivery, and whose neonate has also completed the Week 4 visit (or 41 weeks PMA, whichever is later) or died prior to this timepoint.

For first database lock: from randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later for the first database lock; for second database lock: through 12 weeks after birth
Time to First Occurrence of IUT or Hydrops Fetalis
Časové okno: From randomization to delivery of baby (Up to 38 weeks)

Time to first occurrence of IUT or hydrops fetalis will be reported.

From randomization to delivery of baby (Up to 38 weeks)
Neonatal Mortality and Morbidity Index (NMMI) in Liveborn Neonates
Časové okno: Through 38 weeks PMA or at discharge if earlier than 38 weeks PMA

The NMMI will be assessed with the following categories: fatal: fetal/neonatal death; major morbidity: any of intraventricular hemorrhage grade 3/4, seizures, hypoxic-ischemic encephalopathy, necrotizing enterocolitis stage 2/3, respiratory distress syndrome requiring mechanical ventilation, bronchopulmonary dysplasia requiring oxygen support, or persistent pulmonary hypertension; Minor morbidity: anemia requiring simple transfusion, hyperbilirubinemia requiring an exchange transfusion, hypotension requiring treatment, intraventricular hemorrhage grade 1/2, necrotizing enterocolitis stage 1, or respiratory distress syndrome not requiring mechanical ventilation; None: no major or minor morbidities described above. Hyperbilirubinemia requiring phototherapy will be classified in this category'

Through 38 weeks PMA or at discharge if earlier than 38 weeks PMA
Number of IUT's Received During the Pregnancy
Časové okno: From randomization to delivery of baby (Up to 38 weeks)

Number of IUT's received during the pregnancy will be reported.

From randomization to delivery of baby (Up to 38 weeks)
Percentage of Pregnancies With Fetal Loss
Časové okno: Time to delivery of baby (Up to 38 weeks)

Percentage of pregnancies with fetal loss will be reported.

Time to delivery of baby (Up to 38 weeks)
Percentage of Pregnancies With Fetal or Neonatal Death
Časové okno: Through Week 4 or 41 weeks PMA

Percentage of pregnancies with fetal or neonatal death (through the neonatal period) as a result of HDFN will be reported.

Through Week 4 or 41 weeks PMA
Percentage of Pregnancies With Hydrops Fetalis
Časové okno: Up to 41 weeks PMA

Percentage of pregnancies with hydrops fetalis will be reported. Hydrops fetalis is defined as the presence of >=2 abnormal fluid collections in the fetus or neonate, such as ascites, pleural effusions, pericardial effusion, and generalized skin edema (skin thickness >5 mm).

Up to 41 weeks PMA
Percentage of Pregnancies Receiving IUT During Pregnancy
Časové okno: Up to 35 weeks of GA period

Percentage of pregnancies receiving IUT during pregnancy will be reported.

Up to 35 weeks of GA period
Gestational Age (GA) at First IUT
Časové okno: Up to 35 weeks of GA period

GA at first IUT will be reported.

Up to 35 weeks of GA period
Percentage of Pregnancies Receiving >1 IUT During Pregnancy
Časové okno: Up to 35 weeks of GA period

Percentage of pregnancies receiving >1 IUT during pregnancy will be reported.

Up to 35 weeks of GA period
Percentage of Pregnancies Receiving IUT or HDFN Resulting in Fetal Demise (Less Than) <GA Week 20
Časové okno: Up to 20 weeks

Percentage of pregnancies receiving IUT or HDFN resulting in fetal demise <GA Week 20 will be reported.

Up to 20 weeks
Gestational Age at Delivery
Časové okno: Up to 38 weeks

Gestational age at delivery will be reported.

Up to 38 weeks
Percentage of Pregnancies With Neonatal Death Through the Neonatal Period
Časové okno: From randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later

Percentage of pregnancies with neonatal death through the neonatal period will be reported.

From randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later
Percentage of Liveborn Neonates With HDFN-related Morbidities Other Than Anemia and Hyperbilirubinemia or Jaundice
Časové okno: From day of birth up to 4 weeks

Percentage of liveborn neonates with HDFN-related morbidities other than anemia and hyperbilirubinemia or jaundice will be reported.

From day of birth up to 4 weeks
Absolute Weight of Liveborn Neonates or Infants
Časové okno: Up to 104 weeks

Absolute weight of liveborn neonates or infants will be reported.

Up to 104 weeks
Change From Baseline in Weight of Liveborn Neonates or Infants
Časové okno: Baseline to up to 104 weeks

Change from baseline in weight of liveborn neonates or infants will be reported.

Baseline to up to 104 weeks
Liveborn Neonates Length of Stay in Neonatal Intensive Care Unit
Časové okno: From day of birth up to 27 days

Liveborn neonates length of stay in neonatal intensive care unit will be reported.

From day of birth up to 27 days
Percentage of Liveborn Neonates Receiving Exchange Transfusions for HDFN
Časové okno: From day of birth up to 27 days

Percentage of liveborn neonates receiving exchange transfusions for HDFN will be reported.

From day of birth up to 27 days
Number of Neonatal Exchange Transfusions per Liveborn Neonate
Časové okno: From day of birth up to 27 days

Number of neonatal exchange transfusions per liveborn neonate will be reported.

From day of birth up to 27 days
Percentage of Liveborn Neonates or Infants with Simple Transfusions for HDFN
Časové okno: For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks

Percentage of liveborn neonates or infants with simple transfusions for HDFN through the neonatal period (for the first database lock) or 12 weeks (for the second database lock) after birth will be reported.

For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Number of Simple Transfusions for HDFN per Liveborn Neonate or Infant
Časové okno: For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks

Number of simple transfusions for HDFN per liveborn neonate or infant through the neonatal period (for the first database lock) or 12 weeks (for the second database lock) after birth will be reported.

For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Percentage of Liveborn Neonates With Hyperbilirubinemia Treated With Phototherapy
Časové okno: From day of birth up to 27 days

Percentage of liveborn neonates with hyperbilirubinemia treated with phototherapy will be reported.

From day of birth up to 27 days
Number of Days of Phototherapy Received for Hyperbilirubinemia per Liveborn Neonate
Časové okno: From day of birth up to 27 days

Number of days of phototherapy received for hyperbilirubinemia per liveborn neonate will be reported.

From day of birth up to 27 days
Percentage of Liveborn Neonates or Infants Receiving Intravenous Immunoglobulin (IVIg) for HDFN Treatment
Časové okno: For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks

Percentage of liveborn neonates or infants receiving IVIg for HDFN treatment will be reported.

For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Number of Maternal Deaths
Časové okno: Form randomization up to 24 weeks postpartum

Number of maternal deaths will be reported.

Form randomization up to 24 weeks postpartum
Number of Participants with Adverse Events (AEs)
Časové okno: From randomization up to 24 weeks postpartum

Number of participants with AEs, serious adverse events, and AEs of special interest (AESIs), AE's leading to discontinuations, infections, serious infections, infusion reactions, and hypersensitivity reactions will be reported. Treatment-emergent adverse events associated with the following situations are considered as AESIs: hypoalbuminemia, clinically significant bleeding with a corresponding placental finding on ultrasound, maternal infections that led to clinically significant morbidities or mortalities in fetus or neonates, Infections that are severe or require intravenous (IV) anti-infective or operative or invasive intervention in maternal participants or neonates or infants, and infants with hypogammaglobulinemia.

From randomization up to 24 weeks postpartum
Number of Maternal Pregnancy Complications
Časové okno: Up to 38 weeks

Number of maternal pregnancy complications will be reported.

Up to 38 weeks
Number of IUT Related complications
Časové okno: Up to 35 weeks of GA period

Number of participants with IUT related complications will be reported.

Up to 35 weeks of GA period
Percentage of Pregnancies With Cesarean Delivery, Preterm Birth, Fetal Growth, and Preeclampsia
Časové okno: Up to 38 weeks of GA period

Percentage of pregnancies with cesarean delivery, cesarean delivery due to IUT complications, preterm birth <GA week 28, preterm birth <GA week 32, preterm birth <GA week 34, preterm birth <GA week 37, fetal growth restriction, and preeclampsia will be reported.

Up to 38 weeks of GA period
Percentage of Liveborn Neonates or Infants Who Died
Časové okno: Up to 104 weeks

Percentage of liveborn neonates or infants who died will be reported.

Up to 104 weeks
Percentage of Liveborn Neonates or Infants With AEs
Časové okno: Up to 104 weeks

Percentage of liveborn neonates or infants with AEs, SAEs, AESIs, infections, serious infections will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Any event requiring hospitalization (or prolongation of hospitalization) that occurs during participation in the study must be reported as an SAE.

Up to 104 weeks
Percentage of Liveborn Neonates or Infants Receiving IVIg for Non-HDFN Indications
Časové okno: Up to 104 weeks

Percentage of liveborn neonates or infants receiving IVIg for non-HDFN indications will be reported.

Up to 104 weeks
Percentage of Liveborn Neonates or Infants With Abnormal Hearing
Časové okno: Up to 104 weeks

Percentage of liveborn neonates or infants with abnormal hearing will be reported.

Up to 104 weeks
Bayley Scales of Infant Development and Toddler Development
Časové okno: Week 52 and 104

The Bayley Scales of infant development is considered the standard assessment of early child development and includes cognition, language, motor skills, social emotional, and adaptive behavior will be reported. The Bayley Scales (3rd edition) are reference standards that measure infant and toddler development in five areas: cognition, language, motor skills, social-emotional and adaptive behavior. The cognition, language and motor skills scales are directly administered to the infant, while social-emotional, and adaptive behavior scales are caregiver questionnaires. The scores are standardized using norm reference samples with representative demographics and age adjusted for prematurity. Higher scores in the Bayley Scales indicate better outcomes.

Week 52 and 104
Change From Baseline in Generalized Anxiety Disorder 7-Item (GAD7) Over time During Pregnancy and Postpartum
Časové okno: Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in GAD7 over time during pregnancy and postpartum will be reported. The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. The recall period for all items is the past 2 weeks. Responses to all items are rated on a 4-point Likert scale ranging from 0 "not at all" to 3 "nearly every day". The total score ranges from 0 to 21, with higher scores indicating higher severity of anxiety symptoms.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Domain Score
Časové okno: Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in SF-36v2 acute form domain score will be reported. The SF-36 version 2 acute is a self-administered, 36-item questionnaire measuring health-related quality of life and includes 8 domains that measure physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality social functioning, role limitations due to emotional problems, and mental health. The 8 domains can be aggregated into 2 summary scales that reflect physical and mental health: a physical component summary and a mental component summary. Responses to all items are rated on a 3, 5, or 6-point Likert scale, with higher scores indicating better health status.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Change From Baseline in EuroQol Five-dimension Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) Score
Časové okno: Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in EQ-5D-5L visual analogue score will be reported. The EQ-5D descriptive system is comprised of 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety or depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "no problems" to "extreme problems", with higher scores indicating better quality of life. EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-VAS score ranges from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state. Higher score indicates good health state.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Change From Baseline in EuroQol 5-Dimension Descriptive (EQ-5D) Index Score
Časové okno: Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in EQ-5D index score will be reported. The EQ-5D descriptive system is comprised of 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety or depression. The EQ-5D-5L descriptive system uses a 5-point Likert response scale ranging from "no problems" to "extreme problems", with higher scores indicating better quality of life.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Infant Health-Related Quality of Life Instrument (IQI) Score for Neonate or Infant Overtime
Časové okno: Weeks 4, 8 and 52

IQI score for neonate or infant will be reported. The IQI consists of 7 health attributes including sleeping, feeding, breathing, stooling or poo, mood, skin, and interaction. Responses to all items are rated on a 4-point Likert scale, with higher scores indicating better quality of life.

Weeks 4, 8 and 52

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Ředitel studie: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

20. prosince 2023

Primární dokončení (Odhadovaný)

5. srpna 2027

Dokončení studie (Odhadovaný)

8. října 2029

Termíny zápisu do studia

První předloženo

13. června 2023

První předloženo, které splnilo kritéria kontroly kvality

13. června 2023

První zveřejněno (Aktuální)

22. června 2023

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

3. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • CR109199
  • 2021-002359-12 (Číslo EudraCT)
  • 80202135EBF3001 (Jiný identifikátor: Janssen Research & Development, LLC)
  • 2022-502629-16-00 (Identifikátor registru: EUCT number)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit